NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Alnylam Pharmaceuticals, Inc. ALNY
18 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$3.7B
▲ 65.2% vs FY2024
EPS · FY25
$2.33
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
73.3%
Net margin · FY25
8.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 3.7B
Revenue, FY2025 · full 18-year series below
Revenue
Net income
8 cents of every revenue dollar became profit this year.
Per share
USD 2.33
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
73.3%
Return on equity, FY2025
ROE
Operating margin13.5%
Net margin8.4%
Return on assets6.8%
Each USD of equity produced 73 cents of profit this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+49.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+53.0%
+49.8%
+27.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.13B
Shares outstanding, FY2025
Change, 5 years+13.7%
Change, 10 years+55.6%
The share count grew 14% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 5.0B
total assets, end of FY2025
Total assetsUSD 5.0B
EquityUSD 789.2M
CashUSD 1.7B
Current ratio2.76×
Equity funds 16% of total assets.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Revenue $B
3.7
2.2
1.8
1.0
0.8
0.5
0.2
0.1
0.1
0.0
·
·
·
·
·
0.1
0.1
0.1
Operating income $B
0.5
−0.2
−0.3
−0.8
−0.7
−0.8
−0.9
−0.8
−0.5
−0.4
−0.3
−0.4
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EBITDA $B
0.6
−0.1
−0.2
−0.7
−0.7
−0.8
−0.9
−0.8
−0.5
−0.4
−0.3
−0.4
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
−0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
Net income $B
0.3
−0.3
−0.4
−1.1
−0.9
−0.9
−0.9
−0.8
−0.5
−0.4
−0.3
−0.4
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
2.33
−2.18
−3.52
−9.30
−7.20
−7.46
−8.11
−7.57
−5.42
−4.79
−3.45
−4.85
−1.45
−2.11
−1.36
−1.04
−1.14
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
73.3
·
·
−526.1
−106.3
−69.9
−64.7
−49.6
−36.5
−37.5
−26.4
−59.7
−44.1
−84.1
−41.7
−25.9
−25.0
−13.0
Shares out B
0.13
0.13
0.13
0.12
0.12
0.12
0.11
0.10
0.10
0.09
0.09
0.08
0.06
0.05
0.04
0.04
0.04
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
50 of 50
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed